Cefaclor manufacturers and suppliers in india

Cefaclor

Properties

Boiling point:: 713.4±60.0 °C(Predicted)

Density: 1.3575 (rough estimate)

refractive index: 1.6100 (estimate)

storage temp.: under inert gas (nitrogen or Argon) at 2–8 °C

solubility: 1 M HCl: 50 mg/mL, clear to very faintly turbid, yellow

pka: pKa 1.5±0.2(H2O) (Uncertain)

form: powder

color: Crystal

Water Solubility: 10g/L(temperature not stated)

BRN: 8176092

BCS Class: 3

InChI: InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1

InChIKey: QYIYFLOTGYLRGG-GPCCPHFNSA-N

SMILES: N12[C@@]([H])([C@H](NC([C@H](N)C3=CC=CC=C3)=O)C1=O)SCC(Cl)=C2C(O)=O

Safety Information

Symbol(GHS): GHS08

Signal word: Danger

Hazard statements: H317-H334

Precautionary statements: P280g-P284-P304+P340-P342+P311a-P501a-P261-P280-P342+P311

Hazard Codes: Xn,Xi

Risk Statements: 42/43

Safety Statements: 22-36/37-45

WGK Germany: 2

RTECS: XI0363000

HS Code: 29349990

Toxicity: TDLo orl-cld: 131 mg/kg/7D-I:MSK,SKN CMAJAX 126,1032,82

Use

Cefaclor (Ceclor) is an orally active semisyntheticcephalosporin that was introduced in the American market in1979. It differs structurally from cephalexin in that the 3-methyl group has been replaced by a chlorine atom. It issynthesized from the corresponding 3-methylenecepham sulfoxideester by ozonolysis, followed by halogenation of theresulting β-ketoester. The 3-methylenecepham sulfoxideesters are prepared by rearrangement of the corresponding 6-acylaminopenicillanic acid derivative. Cefaclor is moderatelystable in acid and achieves enough oral absorption to provideeffective plasma levels (equal to about two-thirds of thoseobtained with cephalexin). The compound is apparentlyunstable in solution, since about 50% of its antimicrobial activityis lost in 2 hours in serum at 37°C. The antibacterialspectrum of activity is similar to that of cephalexin, but it isclaimed to be more potent against some species sensitiveto both agents. Currently, the drug is recommended for thetreatment of non–life-threatening infections caused by H.influenzae, particularly strains resistant to ampicillin.